Impaired antioxidant HDL function is associated with premature myocardial infarction

European Journal of Clinical Investigation

Volumn 45, Issue 7, 2015, Pages 731-738

  Distelmaier, Klaus ^a   Wiesbauer, Franz ^a   Blessberger, Hermann ^b   Oravec, Stanislav ^c   Schrutka, Lore ^a   Binder, Christina ^a   Dostal, Elisabeth ^d   Schillinger, Martin ^a   Wojta, Johann ^a,e   Lang, Irene M ^a   Maurer, Gerald ^a   Huber, Kurt ^f   Goliasch, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

^c Faculty of Natural Sciences   (Slovakia)

^d Krankenanstalten Dr Dostal   (Austria)

^e Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^f WILHELMINEN HOSPITAL   (Austria)

Author keywords

Acute myocardial infarction; Antioxidant function; High density lipoprotein; Premature coronary artery disease

Indexed keywords

HIGH DENSITY LIPOPROTEIN; ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PREMATURE MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RISK FACTOR; ADOLESCENT; AGED; CLINICAL TRIAL; COMPLICATION; CORONARY ARTERY DISEASE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; YOUNG ADULT;

EID: 84933279080     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12466     Document Type: Article

References (46)

1. Choudhury L, Marsh JD. Myocardial infarction in young patients. Am J Med 1999;107:254-61.
2. Goliasch G, Wiesbauer F, Grafl A, Ponweiser E, Blessberger H, Tentzeris I et al. The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (
3. Wiesbauer F, Blessberger H, Azar D, Goliasch G, Wagner O, Gerhold L et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). Eur Heart J 2009;30:1073-9.
4. Goliasch G, Oravec S, Blessberger H, Dostal E, Hoke M, Wojta J et al. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (
5. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
6. Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009;206:611-6.
7. Silbernagel G, Schottker B, Appelbaum S, Scharnagl H, Kleber ME, Grammer TB et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 2013;34:3563-71.
8. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35.
9. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 2011;58:2068-75.
10. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383-93.
11. de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 2012;222:390-4.
12. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-17.
13. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013;127:891-904.
14. Shah AS, Tan L, Long JL, Davidson WS. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013;54:2575-85.
15. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67.
16. Goliasch G, Wiesbauer F, Kastl SP, Katsaros KM, Blessberger H, Maurer G et al. Premature myocardial infarction is associated with low serum levels of Wnt-1. Atherosclerosis 2012;222:251-6.
17. Patel PJ, Khera AV, Wilensky RL, Rader DJ. Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail 2013;15:1215-9.
18. Yin F, Lawal A, Ricks J, Fox JR, Larson T, Navab M et al. Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein. Arterioscler Thromb Vasc Biol 2013;33:1153-61.
19. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57:392-410.
20. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116-28.
21. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
22. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases working group on cardiovascular complications of Type 1 diabetes mellitus. Circulation 2005;111:3489-93.
23. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.
24. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42.
25. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2006;2:504-11.
26. Holy EW, Besler C, Reiner MF, Camici GG, Manz J, Beer JH et al. High-density lipoprotein from patients with coronary heart disease loses anti-thrombotic effects on endothelial cells: impact on arterial thrombus formation. Thromb Haemost 2014;112:1024-35.
27. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013;123:3815-28.
28. Farbstein D, Levy AP. HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther 2012;10:353-61.
29. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000;43:312-20.
30. Shao B, Pennathur S, Heinecke JW. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 2012;287:6375-86.
31. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A 2008;105:12224-9.
32. Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 2010;12:135-42.
33. McEneny J, Blair S, Woodside JV, Murray L, Boreham C, Young IS. High-density lipoprotein subfractions display proatherogenic properties in overweight and obese children. Pediatr Res 2013;74:279-83.
34. He BM, Zhao SP, Peng ZY. Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis. J Cell Biochem 2013;114:2431-6.
35. Park KH, Shin DG, Cho KH. Dysfunctional lipoproteins from young smokers exacerbate cellular senescence and atherogenesis with smaller particle size and severe oxidation and glycation. Toxicol Sci 2014;140:16-25.
36. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116:3090-100.
37. Santos-Gallego CG, Badimon JJ, Rosenson RS. Beginning to understand high-density lipoproteins. Endocrinol Metab Clin North Am 2014;43:913-47.
38. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012;125:1905-19.
39. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23:1881-8.
40. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012;60:508-16.
41. Akinkuolie AO, Paynter NP, Padmanabhan L, Mora S. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes 2014;7:55-63.
42. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013;128:1189-97.
43. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-63.
44. Kelesidis T, Currier JS, Huynh D, Meriwether D, Charles-Schoeman C, Reddy ST et al. A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res 2011;52:2341-51.
45. Kelesidis T, Reddy ST, Huynh D, Meriwether D, Fogelman AM, Navab M et al. Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis 2012;11:87.
46. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.